European Addiction-Focused Indivior Stock Falls As Drugmaker Warns Lower Revenues In 2025 Despite Q4 Earnings Beat

Generado por agente de IAMarcus Lee
jueves, 20 de febrero de 2025, 2:27 pm ET1 min de lectura
INDV--

Indivior PLC (NASDAQ: INDV), a European pharmaceutical company specializing in addiction treatment, saw its stock price fall despite reporting a Q4 earnings beat. The company's shares declined following its fiscal year 2025 guidance, which fell short of market expectations. Indivior's revenue outlook for 2025 is projected to decrease by 17% at the midpoint of its forecast range, primarily due to a more than 50% drop in revenue from its Suboxone film treatment.

Comentarios



Add a public comment...
Sin comentarios

Aún no hay comentarios